Elacestrant monotherapy (HR+/HER2- ESR1-mutant metastatic post-AI/CDK4/6i)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Components | DRUG-ELACESTRANT |
|---|
| ID | REG-ELACESTRANT-BREAST |
|---|---|
| Type | Regimen |
| Status | reviewed 2026-04-27 | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-EMERALD-BIDARD-2022 SRC-ESMO-BREAST-METASTATIC-2024 SRC-NCCN-BREAST-2025 |
Notes
EMERALD: ESR1-mutant cohort PFS 3.8 vs 1.9 mo (HR 0.55). Benefit enriched in patients with ≥12 mo prior CDK4/6i exposure (post-hoc). ESR1-mutation testing (ctDNA preferred — polyclonal, acquired on AI) required pre-start. Other oral SERDs in late development (camizestrant, giredestrant, imlunestrant); elacestrant is the first FDA-approved (2023).
Used By
Handbook Chapters
HB-BREAST-HR-POS-HER2-NEG-1L- HR+/HER2- metastatic breast cancer: first-line reasoning
Indication
IND-BREAST-HR-POS-2L-ESR1-ELACESTRANT- IND-BREAST-HR-POS-2L-ESR1-ELACESTRANT